1/30
07:00 am
tnxp
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Medium
Report
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
1/17
01:11 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was upgraded by analysts at
Wall Str
Low
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was upgraded by analysts at
Wall Str
1/6
07:00 am
tnxp
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Low
Report
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
1/3
01:08 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
Medium
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
12/30
08:12 am
tnxp
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
Medium
Report
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
12/29
08:12 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
12/29
08:01 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
12/29
07:57 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Medium
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
12/29
07:45 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Medium
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
12/16
07:51 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
12/16
07:00 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
12/9
07:00 am
tnxp
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Low
Report
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel